Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.
To explore the genetic basis of clonal hematopoiesis and its consequences, researchers analyzed genotyping data for more than 151,000 UK Biobank participants.
Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The partners will map genomic variation and study its effects on patient outcomes to provide a resource for the prognosis of cancer patients and to help guide treatment for them.
The deal covers tests based on bone marrow and peripheral blood for hematologic cancers.
The Associated Press reports that gene-edited food may soon be for sale.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.